POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial

S Danese,B Feagan,S Schreiber,S Vermeire,K Harris,K Hasegawa,X L.U,A Oortwijn,H Patel,W Sandborn,L Peyrin-Biroulet

doi:10.1016/j.jval.2021.11.1061

POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial

S Danese, B Feagan + Show 9 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.1061

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jan 1, 2022
Citations: 1	License type: elsevier-specific: oa user license

Affiliation: Humanitas University, Western University, University Hospital Schleswig-Holstein, Gilead Sciences (United States), Galapagos (Belgium), Galapagos (Netherlands), University of California, San Diego, Centre Hospitalier Universitaire de Nancy

#Work Productivity And Activity Impairment #Work Productivity + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SELECTION, a randomized, double-blind, placebo-controlled phase 2b/3 trial (NCT02914522), evaluated filgotinib (FIL; JAK1 preferential inhibitor) in moderately to severely active ulcerative colitis. We assessed FIL’s effects on EQ-5D-5L utility and Work Productivity and Activity Impairment (WPAI) scores during the SELECTION study.

Full Text